ArticleHuman vaccines & immunotherapeutics2025
A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the integration of nanoparticles with chimeric antigen receptor T-cell (CAR-T) therapy has advanced rapidly, garnering considerable attention from both academic and industrial sectors. However, a comprehensive analysis of key trends and emerging frontiers in this interdisciplinary field remains lacking. To address this gap, we conducted a bibliometric analysis of 515 publications indexed in the Web of Science Core Collection from 2013 to 2024. Using VOSviewer, CiteSpace, and R-bibliometrix, we analyzed publication trends, influential journals, national and institutional contributions, leading authors, and high-impact references. Keyword co-occurrence analyses were performed in VOSviewer, applying a minimum occurrence threshold of five. Citation bursts and clustering analyses of references and keywords were conducted using CiteSpace with default detection settings. Our analysis revealed major research hotspots, especially the optimization of CAR-T cell manufacturing processes and strategies to overcome barriers within the immunosuppressive tumor microenvironment. Looking forward, research is expected to focus increasingly on nanotechnologies such as lipid nanoparticles, precision cell tracking, and siRNA delivery platforms. These innovations hold substantial promise for enhancing the therapeutic efficacy of CAR-T therapies, particularly in the treatment of solid tumors, where conventional approaches remain inadequate. By identifying emerging directions and influential research trends, our analysis highlights the dynamic synergy between nanoparticles and CAR-T therapies, helping to fuel groundbreaking advances in tumor immunotherapy. This study provides data-driven insights that inform clinical trial design, foster interdisciplinary collaboration, and demonstrate the field's strong potential to transform future cancer treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.